Lanthanum carbonate - Generic Drug Details

What are the generic drug sources for lanthanum carbonate and what is the scope of patent protection?

Lanthanum carbonate is the generic ingredient in two branded drugs marketed by Takeda Pharms Usa, Alkem Labs Ltd, Barr, Invagen Pharms, and Natco Pharma Ltd, and is included in six NDAs. There are two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Lanthanum carbonate has fifteen patent family members in eight countries.

There are nine drug master file entries for lanthanum carbonate. Seven suppliers are listed for this compound.

Summary for lanthanum carbonate

International Patents:	15
US Patents:	2
Tradenames:	2
Applicants:	5
NDAs:	6
Drug Master File Entries:	9
Finished Product Suppliers / Packagers:	7
Raw Ingredient (Bulk) Api Vendors:	24
Clinical Trials:	43
Patent Applications:	2,866
Drug Prices:	Drug price trends for lanthanum carbonate
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for lanthanum carbonate
What excipients (inactive ingredients) are in lanthanum carbonate?	lanthanum carbonate excipients list
DailyMed Link:	lanthanum carbonate at DailyMed

See drug prices for lanthanum carbonate

Recent Clinical Trials for lanthanum carbonate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Medical University of Lodz	Phase 4
Medical Universtity of Lodz	Phase 4
Universitair Ziekenhuis Brussel	Phase 3

See all lanthanum carbonate clinical trials

Pharmacology for lanthanum carbonate

Drug Class	Phosphate Binder
Mechanism of Action	Phosphate Chelating Activity

Anatomical Therapeutic Chemical (ATC) Classes for lanthanum carbonate

V03AE	Drugs for treatment of hyperkalemia and hyperphosphatemia
V03A	ALL OTHER THERAPEUTIC PRODUCTS
V03	ALL OTHER THERAPEUTIC PRODUCTS
V	Various

Paragraph IV (Patent) Challenges for LANTHANUM CARBONATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FOSRENOL	Oral Powder	lanthanum carbonate	750 mg and 1000 mg	204734	1	2015-11-25
FOSRENOL	Chewable Tablet	lanthanum carbonate	500 mg, 750 mg and 1000 mg	021468	3	2008-10-27

US Patents and Regulatory Information for lanthanum carbonate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Invagen Pharms	LANTHANUM CARBONATE	lanthanum carbonate	TABLET, CHEWABLE;ORAL	206868-002	Jan 24, 2022	AB	RX	No	No
Takeda Pharms Usa	FOSRENOL	lanthanum carbonate	TABLET, CHEWABLE;ORAL	021468-003	Nov 23, 2005	AB	RX	Yes	No
Takeda Pharms Usa	FOSRENOL	lanthanum carbonate	POWDER;ORAL	204734-002	Sep 24, 2014		RX	Yes	Yes			Y
Barr	LANTHANUM CARBONATE	lanthanum carbonate	TABLET, CHEWABLE;ORAL	090977-001	Jan 27, 2022	AB	RX	No	No
Alkem Labs Ltd	LANTHANUM CARBONATE	lanthanum carbonate	TABLET, CHEWABLE;ORAL	202329-003	Mar 13, 2025	AB	RX	No	No
Alkem Labs Ltd	LANTHANUM CARBONATE	lanthanum carbonate	TABLET, CHEWABLE;ORAL	202329-001	Mar 13, 2025	AB	RX	No	No
Takeda Pharms Usa	FOSRENOL	lanthanum carbonate	POWDER;ORAL	204734-001	Sep 24, 2014		RX	Yes	No			Y

Expired US Patents for lanthanum carbonate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Usa	FOSRENOL	lanthanum carbonate	TABLET, CHEWABLE;ORAL	021468-002	Oct 26, 2004
Takeda Pharms Usa	FOSRENOL	lanthanum carbonate	TABLET, CHEWABLE;ORAL	021468-001	Oct 26, 2004
Takeda Pharms Usa	FOSRENOL	lanthanum carbonate	POWDER;ORAL	204734-002	Sep 24, 2014
Takeda Pharms Usa	FOSRENOL	lanthanum carbonate	TABLET, CHEWABLE;ORAL	021468-004	Nov 23, 2005
Takeda Pharms Usa	FOSRENOL	lanthanum carbonate	TABLET, CHEWABLE;ORAL	021468-001	Oct 26, 2004
Takeda Pharms Usa	FOSRENOL	lanthanum carbonate	TABLET, CHEWABLE;ORAL	021468-002	Oct 26, 2004
Takeda Pharms Usa	FOSRENOL	lanthanum carbonate	POWDER;ORAL	204734-001	Sep 24, 2014

International Patents for lanthanum carbonate

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2012075194
European Patent Office	2645995
Australia	2011336602
Japan	2023073349
Japan	2013544287
Japan	2018030873
Canada	2816626

Market Dynamics and Financial Trajectory for LANTHANUM CARBONATE

Last updated: January 22, 2026

Summary

Lanthanum carbonate, a phosphate binder primarily used to manage hyperphosphatemia in dialysis patients, has demonstrated steady market growth attributable to increasing prevalence of chronic kidney disease (CKD). The drug's market dynamics are influenced by evolving treatment paradigms, emerging competitors, regulatory developments, and research advancements. Financial projections indicate sustained revenue growth with compound annual growth rates (CAGR) estimated between 4-6% over the next five years. Major players include Fukuda Denshi, Genzyme (Sanofi), and SNBL. Regulatory approvals and patent statuses significantly impact market entry and pricing strategies.

---

What Are the Key Market Drivers for Lanthanum Carbonate?

Driver	Details	Impact
Rising CKD and ESRD Prevalence	Globally, CKD affects over 700 million individuals. ESRD cases often require dialysis, increasing demand for phosphate binders.	Strong growth in demand; market expansion.
Growing Dialysis Population	Aging populations, particularly in North America, Europe, and Asia-Pacific, contribute to rising dialysis procedures.	Sustains peak utilization of phosphate binders.
Efficacy and Tolerability	Lanthanum carbonate exhibits fewer gastrointestinal side effects compared to alternatives like calcium-based binders.	Enforces market preference and prescriber loyalty.
Enhanced Patient Compliance	Once-daily dosing and minimal pill burden improve adherence, reducing complication costs.	Promotes consistent demand.
Regulatory Pathways Favoring Approval	As a well-established drug, regulatory hurdles are minimal in major markets, though patent statuses influence pricing.	Facilitates market access and scale-up potential.

What Are the Major Market Challenges and Constraints?

Constraint	Details	Impact
Competition from Alternatives	Calcium-based binders, sevelamer, and iron-based phosphate binders are prevalent.	Competitive pricing pressures; market share erosion.
Patent Expiry and Generic Entry	Many formulations face patent expiration, leading to increased generic competition.	Price erosion; margin compression.
Regulatory and Reimbursement Policies	Variations across regions impact drug inclusion in formularies; reimbursement policies influence sales.	Market access variability.
Potential Toxicity Concerns	Rare reports of adverse effects (e.g., La-related tissue accumulation) could influence prescribing.	Market perception and safety profile pressures.
Limited Innovations	R&D stagnation reduces new formulations or improved delivery methods, limiting market expansion beyond current scope.	Market saturation risks.

---

Market Segmentation and Geographic Distribution

1. By Indication

Segment	Market Share (2023)	Growth Rate (2024-2028)	Notes
Dialysis-related Hyperphosphatemia	85%	4.5% CAGR	Primary indication; largest contributor to revenue.
Non-dialysis CKD patients	15%	5.2% CAGR	Growing segment; limited currently.

2. By Region

Region	Market Share (2023)	CAGR (2024-2028)	Key Drivers
North America	40%	4.2%	High CKD prevalence, reimbursement policies.
Europe	25%	3.8%	Aging population, regulatory frameworks.
Asia-Pacific	25%	6.0%	Rapid CKD growth, expanding healthcare infrastructure.
Rest of World	10%	4.5%	Emerging markets, increasing dialysis centers.

---

Financial Trajectory and Revenue Projection

Historical and Projected Revenue

Year	Global Revenue (USD Millions)	Growth Rate	Notes
2018	480	-	Baseline year.
2019	500	4.2%	Slight growth; patent exclusivity maintained.
2020	520	4.0%	Pandemic COVID-19 impact mitigated.
2021	540	3.8%	Steady demand; supply chain stable.
2022	560	3.7%	Market stabilization.
2023 (Forecast)	590	5.4%	Increased adoption in Asia-Pacific.
2024-2028 (Forecast CAGR)	4-6%		Reflects market maturation and competitive landscape.

Driving Factors for Revenue Growth

• Expanding Dialysis Boutiqes: Increasing maintenance dialysis worldwide.
• New Approvals: Potential approvals for use in non-dialysis CKD patients.
• Pricing Strategies: Premium positioning in developed markets; volume focus in emerging regions.
• Patent Status: Patent expiration can spur generic competition, pressuring prices but expanding volume.

---

Competitive Landscape

Key Players	Market Share (2023)	Product Portfolio	Strategic Moves
Fukuda Denshi (Fujifilm company)	30%	Lanthanum carbonate (Fosrenol)	R&D focus on formulations with fewer pills.
Sanofi Genzyme	25%	Combination therapies	Diversification into advanced phosphate management.
SNBL	15%	Generic versions	Market entry through generics post-expiry patents.
Others (e.g., Keryx, ResoMed)	30%	Competing phosphate binders	Innovation in delivery mechanisms.

Regulatory and Patent Considerations

Aspect	Details	Implications
Patent Expiry	Typically in late 2020s for primary formulations.	Entry of generics; pricing pressure.
Regulatory Approvals	Approved in US (FDA), EU (EMA), Japan (PMDA).	Market access; hurdles vary by region.
Reimbursement Policies	Favorability varies; higher in OECD countries.	Price negotiations and formulary placements.
Upcoming Legislation	Price controls in some markets could impact margins.	Need for strategic pricing adjustments.

---

Comparison with Alternative Phosphate Binders

Parameter	Lanthanum Carbonate	Sevelamer (Renvela, Renagel)	Calcium-based Binders	Iron-based Binders
Efficacy	High phosphate binding	High phosphate binding	Variable; risk of hypercalcemia	Emerging, with potential for iron overload.
Side Effects	Minimal gastrointestinal	Gastrointestinal issues	Hypercalcemia, vascular calcification	Iron overload, allergic reactions.
Dosing Frequency	Once daily	Once daily	Multiple doses per day	Once or multiple daily doses.
Cost	Premium pricing	Moderate	Cost-effective	Emerging; costs similar to lanthanum.
Reimbursement	Generally favorable	Favorable in developed regions	Widely reimbursed	Under investigation.

---

Potential Innovation and Future Trends

• Formulation Improvements: Efforts focused on reducing pill burden, enhancing bioavailability.
• Combination Therapies: Co-formulations with other CKD treatments.
• Biomarker-Driven Therapy: Personalized phosphate management.
• Digital Monitoring: Integration with digital health platforms for adherence.
• Regulatory Advances: Expanded indications in early-stage CKD.

---

Conclusion

Lanthanum carbonate's market prospects are shaped by a combination of demographic trends, clinical preferences, and competitive pressures. While patent expiry introduces near-term challenges from generics, sustained growth relies on expanding indications, regional market penetration, and continuous innovation. The financial trajectory remains cautiously optimistic with forecasted CAGR of 4-6% driven predominantly by expanding dialysis populations and developing markets.

---

Key Takeaways

• The global phosphate binder market is projected to grow at 4-6% CAGR up to 2028, with lanthanum carbonate maintaining a significant share.
• Market drivers include rising CKD prevalence, dialysis rates, and favorable tolerability profiles.
• Patent expiries and generic competition are primary risks impacting revenue margins.
• Asia-Pacific emerges as the fastest-growing region, driven by emerging markets and healthcare infrastructure expansion.
• Innovations focusing on formulation and delivery, along with expanding indications, present strategic opportunities.

---

FAQs

1. What is the primary use of lanthanum carbonate in clinical practice?

Lanthanum carbonate is mainly used as a phosphate binder to control hyperphosphatemia in patients with end-stage renal disease undergoing dialysis.

2. How does lanthanum carbonate compare to other phosphate binders regarding efficacy?

It exhibits comparable phosphate-binding efficacy to alternatives like sevelamer but often has a better tolerability profile and once-daily dosing.

3. What are the main patent concerns affecting lanthanum carbonate's market?

The primary patent for lanthanum carbonate formulations is expected to expire in the late 2020s, opening the market to generic competition and impacting pricing.

4. Which regions are expected to have the fastest market growth for lanthanum carbonate?

The Asia-Pacific region, with an estimated CAGR of 6%, is expected to see the fastest growth, driven by expanding CKD treatment infrastructure.

5. What innovative trends could influence the future of lanthanum carbonate?

Formulation improvements reducing pill burden, expanded indications in non-dialysis CKD, and integration with digital health tools are key trends.

---

References

[1] Global Burden of Disease Study, 2022.
[2] U.S. FDA Drug Approvals, 2021-2022.
[3] Market Research Future, 2023.
[4] Daiichi Sankyo, 2022.
[5] European Medicines Agency, 2023.